Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study

Abstract SAR439459 (SAR'459), a “second‐generation” human anti‐transforming growth factor beta (TGFβ) monoclonal antibody, enhances the activity of immune checkpoint inhibitors. In this phase I/Ib study, we evaluated the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of SAR'...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Joaquina C. Baranda, Debbie Robbrecht, Ryan Sullivan, Bernard Doger, Armando Santoro, Minal Barve, Jean‐Jacques Grob, Oliver Bechter, Maria Vieito, Maria Jose deMiguel, Dirk Schadendorf, Melissa Johnson, Clemence Pouzin, Cathy Cantalloube, Rui Wang, Jooyun Lee, Xiaofei Chen, Brigitte Demers, Amele Amrate, Giovanni Abbadessa, F. Stephen Hodi
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Wiley 2024-06-01
Seri Bilgileri:	Clinical and Translational Science
Online Erişim:	https://doi.org/10.1111/cts.13854
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!